<DOC>
	<DOCNO>NCT00121992</DOCNO>
	<brief_summary>This prospective , non-blinded randomized phase III trial . Patients post-surgically stratified inclusion first accord participate institution , accord menopausal status randomly assign receive either : - TAC : Docetaxel 75 mg/m2 1 hour intravenous ( i.v . ) infusion day 1 every 3 week ( q3w ) combination doxorubicin 50 mg/m2 i.v . bolus cyclophosphamide 500 mg/m2 i.v . bolus day 1 every 3 week . - FAC : 5-fluorouracil 500 mg/m2 i.v . bolus day 1 every 3 week combination doxorubicin 50 mg/m2 i.v . bolus cyclophosphamide 500 mg/m2 i.v . bolus day 1 every 3 week .</brief_summary>
	<brief_title>Docetaxel Combination With Doxorubicin Cyclophosphamide ( TAC ) Versus 5-Fluorouracil Combination With Doxorubicin Cyclophosphamide ( 5 FAC ) Adjuvant Treatment Breast Cancer Patients</brief_title>
	<detailed_description>Primary objective : - To compare disease-free survival ( DFS ) treatment docetaxel combination doxorubicin cyclophosphamide ( TAC ) 5-Fluorouracil combination doxorubicin cyclophosphamide ( FAC ) adjuvant treatment high risk operable breast cancer patient negative axillary lymph node . Secondary objective : - To compare overall survival ( OS ) 2 mention arm . - To compare toxicity quality life 2 mention arm . - To evaluate pathologic marker predict efficacy ( hormonal receptor c-erB-2 ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Written inform consent Operable breast cancer patient ( T1T3 ) negative axillary lymph node ( 10 axillary node dissection ) high risk criterion accord St. Gallen consensus criterion . Histologically proven breast cancer . Interval surgery registration le 60 day . Definitive surgical treatment must either mastectomy , breast conservative surgery . Margins resect specimen surgery must histologically free invasive adenocarcinoma ductal carcinoma insitu ( DCIS ) . Lobular carcinoma insitu consider positive margin . Patients without proven metastatic disease . Estrogen progesterone receptor perform primary tumour prior randomization . Age 18 year 70 year . Karnofsky performance status index &gt; 80 % . Adequate hepatic , renal heart function . Adequate hematology level . Negative pregnancy test Prior systemic anticancer therapy breast cancer ( immunotherapy , hormonotherapy , chemotherapy ) . Prior anthracycline therapy taxoids ( paclitaxel , docetaxel ) malignancy . Prior radiation therapy breast cancer . Bilateral invasive breast cancer . Pregnant , lactate patient . Patients childbearing potential must implement adequate nonhormonal contraceptive measure study treatment . Any T4 N13 M1 breast cancer . Preexisting motor sensory neurotoxicity severity grade 2 NCI criterion . Other serious illness medical condition Past current history neoplasm breast carcinoma . Ipsilateral ductal carcinoma insitu ( DCIS ) breast . Lobular carcinoma insitu ( LCIS ) breast . Chronic treatment corticosteroid unless initiate &gt; 6 month prior study entry low dose Concurrent treatment ovarian hormonal replacement therapy . Prior treatment stop study entry . Definite contraindication use corticosteroid . Concurrent treatment experimental drug . Participation another clinical trial investigational market drug within 30 day prior study entry . Concurrent treatment anticancer therapy . Male patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>High risk node negative breast cancer</keyword>
	<keyword>Disease-Free survival</keyword>
	<keyword>Quality life</keyword>
</DOC>